140 related articles for article (PubMed ID: 9236911)
1. A simple method for the propagation and purification of gamma delta T cells from the peripheral blood of glioblastoma patients using solid-phase anti-CD3 antibody and soluble IL-2.
Yamaguchi T; Fujimiya Y; Suzuki Y; Katakura R; Ebina T
J Immunol Methods; 1997 Jun; 205(1):19-28. PubMed ID: 9236911
[TBL] [Abstract][Full Text] [Related]
2. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-15 effectively potentiates the in vitro tumor-specific activity and proliferation of peripheral blood gammadeltaT cells isolated from glioblastoma patients.
Yamaguchi T; Suzuki Y; Katakura R; Ebina T; Yokoyama J; Fujimiya Y
Cancer Immunol Immunother; 1998 Oct; 47(2):97-103. PubMed ID: 9769118
[TBL] [Abstract][Full Text] [Related]
4. Injury to autologous normal tissues and tumors mediated by lymphokine-activated killer (LAK) cells generated in vitro from peripheral blood mononuclear cells of glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Ohno T
J Hematother; 1999 Feb; 8(1):29-37. PubMed ID: 10192299
[TBL] [Abstract][Full Text] [Related]
5. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
Xiao L; Chen C; Li Z; Zhu S; Tay JC; Zhang X; Zha S; Zeng J; Tan WK; Liu X; Chng WJ; Wang S
Cytotherapy; 2018 Mar; 20(3):420-435. PubMed ID: 29402645
[TBL] [Abstract][Full Text] [Related]
6. Peripheral blood-derived, γ9δ2 t cell-enriched cell lines from glioblastoma multiforme patients exert anti-tumoral effects in vitro.
Marcu-Malina V; Garelick D; Peshes-Yeloz N; Wohl A; Zach L; Nagar M; Amariglio N; Besser MJ; Cohen ZR; Bank I
J Biol Regul Homeost Agents; 2016; 30(1):17-30. PubMed ID: 27049073
[TBL] [Abstract][Full Text] [Related]
7. CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies.
Lopez RD; Xu S; Guo B; Negrin RS; Waller EK
Blood; 2000 Dec; 96(12):3827-37. PubMed ID: 11090067
[TBL] [Abstract][Full Text] [Related]
8. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
[TBL] [Abstract][Full Text] [Related]
9. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract][Full Text] [Related]
10. Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma.
Bryant NL; Suarez-Cuervo C; Gillespie GY; Markert JM; Nabors LB; Meleth S; Lopez RD; Lamb LS
Neuro Oncol; 2009 Aug; 11(4):357-67. PubMed ID: 19211933
[TBL] [Abstract][Full Text] [Related]
11. Enhancing effect of tumor necrosis factor (TNF)-alpha, but not IFN-gamma, on the tumor-specific cytotoxicity of gammadeltaT cells from glioblastoma patients.
Suzuki Y; Fujimiya Y; Ohno T; Katakura R; Yoshimoto T
Cancer Lett; 1999 Jun; 140(1-2):161-7. PubMed ID: 10403555
[TBL] [Abstract][Full Text] [Related]
12. In vitro expansion of CD3/TCR- human thymocyte populations that selectively lack CD3 delta gene expression: a phenotypic and functional analysis.
Poggi A; Biassoni R; Pella N; Paolieri F; Bellomo R; Bertolini A; Moretta L; Mingari MC
J Exp Med; 1990 Nov; 172(5):1409-18. PubMed ID: 2146363
[TBL] [Abstract][Full Text] [Related]
13. T cell functions of IL-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma.
Morita T; Salmeron MA; Hayakawa K; Swanson DA; von Eschenbach AC; Itoh K
Reg Immunol; 1992; 4(4):225-35. PubMed ID: 1476875
[TBL] [Abstract][Full Text] [Related]
14. In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors.
Whiteside TL; Wang YL; Selker RG; Herberman RB
Cancer Res; 1988 Nov; 48(21):6069-75. PubMed ID: 2971433
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells.
Petrini I; Pacini S; Petrini M; Fazzi R; Trombi L; Galimberti S
Eur J Clin Invest; 2009 Sep; 39(9):813-8. PubMed ID: 19522834
[TBL] [Abstract][Full Text] [Related]
16. CD3+4-8-WT31-(T cell receptor gamma+) cells and other unusual phenotypes are frequently detected among spontaneously interleukin 2-responsive T lymphocytes present in the joint fluid in juvenile rheumatoid arthritis. A clonal analysis.
De Maria A; Malnati M; Moretta A; Pende D; Bottino C; Casorati G; Cottafava F; Melioli G; Mingari MC; Migone N
Eur J Immunol; 1987 Dec; 17(12):1815-9. PubMed ID: 2961576
[TBL] [Abstract][Full Text] [Related]
17. Selective activation of resting human gamma delta T lymphocytes by interleukin-2.
Kjeldsen-Kragh J; Quayle AJ; Skålhegg BS; Sioud M; Førre O
Eur J Immunol; 1993 Sep; 23(9):2092-9. PubMed ID: 8370391
[TBL] [Abstract][Full Text] [Related]
18. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cytolytic and proliferative activities of human gamma delta and alpha beta T cells from peripheral blood against various human tumor cell lines.
Ensslin AS; Formby B
J Natl Cancer Inst; 1991 Nov; 83(21):1564-9. PubMed ID: 1683671
[TBL] [Abstract][Full Text] [Related]
20. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
